| h-0d3b8d6197 | Necroptosis-cGAS Feedforward Loop Converts TDP-43 Pathology into Neuroinflammati | 0.46 | 0.38 | MLKL / RIPK1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-b17969bbb7 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targ | 0.46 | 0.50 | DNMT3A | proposed | 2026-04-21 | SDA-2026-04-10-gap-20260410-091440 |
| h-var-b52ba047a5 | Mitochondrial Dysfunction in Neurodegeneration | 0.46 | 0.30 | NDUFV1 | archived | 2026-04-21 | |
| h-var-adc924c2d4 | Alpha-Beta Oscillation Coupling Enhances lncRNA-9969-Mediated Autophagy Through | 0.46 | 0.33 | SST, CREB1, lncRNA-9969, neuronal autophagy pathway | proposed | 2026-04-21 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-var-c4c7aca6dc | ACSL4-Mediated Neuroinflammatory Amplification in Disease-Associated Microglia | 0.46 | 0.71 | ACSL4 | promoted | 2026-04-27 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-40d0524f | Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation | 0.46 | 0.55 | SLC16A1 (MCT1) | proposed | 2026-04-26 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| h-var-2277d00a32 | Astrocytic SPP1 Modulation via STAT3-Dependent Transcriptional Control | 0.46 | 0.36 | SPP1 | superseded | 2026-04-21 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| SDA-2026-04-16-hyp-f | Selective Microglial Senescence Targeting via TREM2 Modulation | 0.46 | 0.29 | TREM2 | proposed | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| h-fdda39f6 | CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation | 0.46 | 0.45 | CX3CL1/CX3CR1 axis; target: CX3CR1 receptor activation | proposed | 2026-04-26 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| h-cc077b4f0d | Intranasal IGFBPL1 Delivery via Olfactory Pathway | 0.46 | 0.45 | IGFBPL1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| h-5d753df0 | Kinase Inhibitor-C1q Structural Convergence for Bifunctional Drug Design | 0.46 | 0.30 | C1QA/C1QB/C1QC, ALK, SYK | proposed | 2026-04-17 | SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e |
| h-46e028b6 | Selective OGA Inhibition as 'Tau Stabilization' Strategy Without Phosphorylation | 0.46 | 0.42 | MGEA5 (OGA) | proposed | 2026-04-13 | SDA-2026-04-13-gap-debate-20260412-094612-a2e3bd09 |
| h-var-c261b9d0cd | CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Del | 0.46 | 0.36 | CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte- | promoted | 2026-04-21 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| hyp-SDA-2026-04-09-g | Glycan-Disrupting Tau Disaggregation | 0.46 | 0.50 | NEU1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Competitive Glycan Decoys for Tau Vesicle Neutralization | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycosyltransferase Modulation for Tau Vesicle Marking | 0.46 | 0.50 | MGAT5 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan-Targeting Tau Vesicle Interceptors | 0.46 | 0.50 | ST6GAL1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan-Based Drug Delivery to Tau Vesicles | 0.46 | 0.50 | ST6GAL1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Lectin-Mediated Autophagy Enhancers | 0.46 | 0.50 | LGALS3 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Glycan Pattern Disruption via Metabolic Intervention | 0.46 | 0.50 | HK1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| hyp-SDA-2026-04-09-g | Vesicle Size-Selective Nanobody Penetration | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | ATP Depletion-Responsive Penetrating Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Membrane Curvature-Responsive Cell-Penetrating Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Cholesterol Depletion-Targeting Nanobody Vectors | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Phosphatidylserine-Targeting Nanobody Chimeras | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | pH-Activated Membrane Fusion Nanobodies | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Tau Conformational Change-Triggered Membrane Disruption | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| hyp-SDA-2026-04-09-g | Temporal Gating Through HSP70 ATPase Cycle Manipulation | 0.46 | 0.50 | HSPA1A | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Phosphorylation-State Dependent Inhibition | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Tau Conformation-Selective HSP70 Inhibition | 0.46 | 0.50 | HSPA1A | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Membrane-Localized HSP90 Disruption | 0.46 | 0.50 | HSP90AA1 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Co-chaperone Hijacking Strategy | 0.46 | 0.50 | HSPA1A | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Competitive Co-chaperone Displacement | 0.46 | 0.50 | FKBP5 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| hyp-SDA-2026-04-09-g | Combinatorial PTM signatures distinguish pathological from physiological tau sta | 0.46 | 0.50 | MAPT | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-09-g | p300/CBP-dependent K280 acetylation nucleates pathogenic tau conformers | 0.46 | 0.50 | EP300 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-09-g | Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seed | 0.46 | 0.50 | CASP2/CASP3 | active | 2026-04-28 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| hyp-SDA-2026-04-08-g | Magnetic Field Stimulation for Memory Consolidation | 0.46 | 0.50 | Cryptochromes (CRY1, CRY2), magnetoreceptor proteins | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Developmental Critical Period Extension for Memory Recovery | 0.46 | 0.50 | PSD-95, CREB, perineuronal net components | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Epigenetic Memory Engram Therapy for Alzheimer's Disease | 0.46 | 0.50 | DNMT3A, CREB-binding protein (CBP) | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Social Memory Network Enhancement Therapy | 0.46 | 0.50 | Oxytocin receptor (OXTR), mirror neuron networks | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Circadian-Spatial Memory Coupling for Navigation Disorders | 0.46 | 0.50 | CLOCK, BMAL1, hippocampal place cells | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Stress-Resilient Memory Formation Protocol | 0.46 | 0.50 | FKBP5, glucocorticoid receptor (GR), BDNF | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Metabolic Memory Support Therapy | 0.46 | 0.50 | AMPK, PGC-1α, mitochondrial complex proteins | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| hyp-SDA-2026-04-08-g | Magnetic Field Sensing-Memory Interface Therapy | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Epigenetic ADCY8 Memory Programming | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Circadian-Spatial Memory Coupling Therapy | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | ADCY8-Mediated Synaptic Tagging for Spatial Memories | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Hippocampal ADCY8 Upregulation for Alzheimer's Navigation Deficits | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | ADCY8-cAMP Memory Consolidation Enhancer | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |